Radiopharm Theranostics Balance Sheet

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Cash & Equivalents	34.52	29.12	18.58	11.7	26.98
Cash & Short-Term Investments	34.52	29.12	18.58	11.7	26.98
Cash Growth	-5.27%	56.75%	58.77%	-56.64%	-
Accounts Receivable	11.36	10.4	0.99	4.47	0.06
Other Current Assets	0.17	0.34	3.29	0.13	0.23
Total Current Assets	46.04	39.85	22.85	16.3	27.26
Net Property, Plant & Equipment	0.05	0.05	0.06	0.07	0
Other Intangible Assets	45.08	46.57	49.09	58.54	56.08
Other Long-Term Assets	-	-	0.04	0.04	0.04
Total Assets	91.17	86.48	72.04	74.95	83.38
Accounts Payable	10.72	9.34	10.86	5.12	2.15
Accrued Expenses	0.58	0.45	0.4	0.29	0.09
Unearned Revenue	1.02	1.72	-	-	-
Other Current Liabilities	2.99	3.42	6.32	7.82	5.63
Total Current Liabilities	15.3	14.93	17.58	13.23	7.88
Other Long-Term Liabilities	25.94	28.68	27.11	16.14	12.54
Total Long-Term Liabilities	25.94	28.68	27.11	16.14	12.54
Total Liabilities	41.23	43.61	44.68	29.37	20.42
Common Stock	209.94	176.56	100.68	97.23	86.76
Additional Paid-in Capital	0.85	0.85	0.85	2.15	-
Accumulated Other Comprehensive Income	13.37	13.12	37.93	10.36	7.11
Retained Earnings	-172.37	-145.73	-111.34	-65.35	-30.91
Total Common Shareholders' Equity	51.78	44.79	28.12	44.38	62.96
Minority Interest	-1.84	-1.92	-0.77	1.19	-
Shareholders' Equity	49.94	42.87	27.35	45.58	62.96
Total Liabilities & Equity	91.17	86.48	72.04	74.95	83.38
Net Cash (Debt)	34.52	29.12	18.58	11.7	26.98
Net Cash Growth	18.54%	56.75%	58.77%	-56.64%	-
Net Cash Per Share	3.53	4.20	14.42	11.48	44.66
Book Value	51.78	44.79	28.12	44.38	62.96
Book Value Per Share	5.30	6.46	21.83	43.54	104.22
Tangible Book Value	6.7	-1.78	-20.96	-14.16	6.89
Tangible Book Value Per Share	0.69	-0.26	-16.27	-13.89	11.40

SEC Filings: 10-K · 10-Q